Refine by
T Cell Receptor Articles & Analysis
36 articles found
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer ...
Among the various forms of immunotherapy, CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) has shown promise, particularly in treating acute lymphoblastic leukemia (ALL), especially in children and young adults. This therapy involves genetically modifying a patient’s ...
The primary focus is on harnessing this technology for modifying primary T cells, a type of white blood cell crucial for the immune response. This approach has opened new avenues for immunotherapy, providing hope for treating conditions like cancer, autoimmune disorders, and genetic diseases. Understanding Primary T ...
Scientists are using a variety of gene delivery strategies to insert new genes into cells. One common biological system is viral gene delivery, where the viral vectors are modified to carry the genes and deliver them to the target cells. ...
Immune receptors are diverse and include pattern recognition receptors (PRR), Toll-like receptors (TLRs), killer activating and killer inhibitory receptors (KAR and KIR), complement receptors, Fc receptors, B cell receptors, and T ...
The emergence of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of certain cancers, providing a promising targeted approach to eliminate cancer cells. However, the monitoring and detection of CAR-T cells in vivo remain a challenge in the ...
The T cell antigen receptor (TCR) is a characteristic marker of T cells, playing a crucial role in the immune system. ...
Cell penetrating peptides provide a solution to this problem. They can form complexes with the therapeutic molecules, allowing them to enter cells together. ...
This cutting-edge technology holds great potential in treating diseases through targeted drug delivery. CAR-T/CAR-NK Cells Development for Drug Delivery Systems As a groundbreaking advancement in immunotherapy, CAR-T (Chimeric Antigen Receptor T-cell) and CAR-NK (Chimeric Antigen ...
Recently, researchers at the University of Pennsylvania, developed a CAR-T therapy to remodel fibrosis by specifically delivering mRNA to T cells. ...
This heightened expression of CD19 makes it a valuable target for treating these diseases. CAR-T cell therapy, an immunotherapy, has demonstrated efficacy in treating B-cell lymphoma by genetically modifying the patient's T cells to carry CD19-specific receptors. ...
The antigen and antibody responses are generally referred to as specific immune responses, which require the participation of B cells and T cells. Other immune cells such as macrophages and NK cells mediate non-specific immune responses, which are part of the body's natural defense system. ...
In addition, it aids in the development of regulatory T cells (Tregs), thereby producing peripheral T cell immune tolerance, as well as regulating the proliferation and differentiation of activated T cells. ...
The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research. ...
One such mechanism are the so-called “immune checkpoints”: these are molecules found on the surface of T cells. When a cell binds both the T-cell receptor (the receptor specific for a given antigen, that gives a T cell its ...
So far, anti-mesothelin antibody-drug conjugates have been successfully used to treat mesothelin-expressing solid tumors, including ovarian cancer, pancreatic cancer, and malignant mesothelioma; and mesothelin targets chimeric antigen receptor (CAR) T cell therapy also showed significant antitumor effects. ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. ...
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells efficacy to treat solid tumors. Dr. ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. ...
Recently, in a study published in Molecular Cancer Therapeutics entitled "Olfactory Receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors," scientists from Moffitt Cancer Research Center identified a novel potential target for CAR-T cells called OR2H1 through research, which may help ...